alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of MBIA Inc. (the Company) on Form 10-Q for the period ending
June 30, 2009 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, C. Edward Chaplin, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted
pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------



|                       
|-----------------------
|/s/ C. Edward Chaplin  
|C. Edward Chaplin      
|Chief Financial Officer
|August 6, 2009
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.4210 Cardiopulmonary bypass vascular catheter, cannula, or tubing. ( a ) *Identification.* A cardiopulmonary bypass vascular catheter, cannula, or tubing is a device used in cardiopulmonary surgery to cannulate the vessels, perfuse the coronary arteries, and to interconnect the catheters and cannulas with an oxygenator. The device includes accessory bypass equipment.
( b ) *Classification.* Class II (performance standards).
EXHIBIT 32.b



CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of American Affordable Housing II Limited Partnership (the "Partnership") on Form 10-Q for the period ended June 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Marc N. Teal, Principal Financial Officer of the general partner of the general partner of the Partnership's general partner, C&M Management Inc., certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge, after due inquiry:



|(1) | The Report fully complies with the requirements of section 13(a)-15 or 15(d)-15 of the Securities and Exchange Act of 1934; and                         
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                         
|(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Partnership.



|                |     |                            
|--------------- | --- | ---------------------------
|Date:           |     |                            
|August 16, 2010 | By: | /s/ Marc N. Teal           
|                |     |                            
|                |     | Marc N. Teal               
|                |     | Principal Financial Officer

A signed original of this written statement required by Section 906, or other

document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Fund and will be retained by the Fund and furnished to the Securities and Exchange Commission or its staff upon request.
# C_2016156EN.01001401.xml

| 2.5.2016 | EN | Official Journal of the European Union | C 156/14 |
| --- | --- | --- | --- |

2.5.2016

EN

Official Journal of the European Union

C 156/14

---

Judgment of the Court (Tenth Chamber) of 17 March 2016 (request for a preliminary ruling from the Hoge Raad der Nederlanden — the Netherlands) — Sonos Europe BV v Staatssecretaris van Financiën

(Case C-84/15) (1)

1

((Reference for a preliminary ruling - Regulation (EEC) No 2658/87 - Customs union and Common Customs Tariff - Tariff classification - Combined Nomenclature - Headings 8517, 8518, 8519, 8527 and 8543 - Stand-alone device designed to retrieve, receive and stream digital audio files in the form of amplified sound))

(2016/C 156/19)

Language of the case: Dutch

Referring court

Referring court

Hoge Raad der Nederlanden

Parties to the main proceedings

Parties to the main proceedings

Applicant: Sonos Europe BV

Applicant:

Defendant: Staatssecretaris van Financiën

Defendant:

Operative part of the judgment

Operative part of the judgment

The Combined Nomenclature listed in Annex I to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff, in the version resulting, successively, from Commission Regulation (EC) No 1031/2008 of 19 September 2008 and Commission Regulation (EC) No 948/2009 of 30 September 2009, must be interpreted as meaning that a stand-alone device designed to retrieve, receive and stream digital audio files in the form of amplified sound, such as that at issue in the main proceedings, must, subject to the referring court’s assessment of all of the facts which it has available to it, be classified under tariff heading 8519 of that nomenclature.

---

(1)  OJ C 146, 4.5.2015.

1

---
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.9 Limitations of exemptions from section 510(k) of the Federal Food, Drug, and Cosmetic Act (the act). The exemption from the requirement of premarket notification (section 510(k) of the act) for a generic type of class I or II device is only to the extent that the device has existing or reasonably foreseeable characteristics of commercially distributed devices within that generic type or, in the case of in vitro diagnostic devices, only to the extent that misdiagnosis as a result of using the device would not be associated with high morbidity or mortality. Accordingly, manufacturers of any commercially distributed class I or II device for which FDA has granted an exemption from the requirement of premarket notification must still submit a premarket notification to FDA before introducing or delivering for introduction into interstate commerce for commercial distribution the device when: ( a ) The device is intended for a use different from the intended use of a legally marketed device in that generic type of device; e.g., the device is intended for a different medical purpose, or the device is intended for lay use where the former intended use was by health care professionals only;
( b ) The modified device operates using a different fundamental scientific technology than a legally marketed device in that generic type of device; e.g., a surgical instrument cuts tissue with a laser beam rather than with a sharpened metal blade, or an in vitro diagnostic device detects or identifies infectious agents by using deoxyribonucleic acid (DNA) probe or nucleic acid hybridization technology rather than culture or immunoassay technology; or
( c ) The device is an in vitro device that is intended: ( 1 ) For use in the diagnosis, monitoring, or screening of neoplastic diseases with the exception of immunohistochemical devices;
( 2 ) For use in screening or diagnosis of familial or acquired genetic disorders, including inborn errors of metabolism;
( 3 ) For measuring an analyte that serves as a surrogate marker for screening, diagnosis, or monitoring life-threatening diseases such as acquired immune deficiency syndrome (AIDS), chronic or active hepatitis, tuberculosis, or myocardial infarction or to monitor therapy;
( 4 ) For assessing the risk of cardiovascular diseases;
( 5 ) For use in diabetes management;
( 6 ) For identifying or inferring the identity of a microorganism directly from clinical material;
( 7 ) For detection of antibodies to microorganisms other than immunoglobulin G (IgG) or IgG assays when the results are not qualitative, or are used to determine immunity, or the assay is intended for use in matrices other than serum or plasma;
( 8 ) For noninvasive testing as defined in § 812.3(k) of this chapter; and
( 9 ) For near patient testing (point of care).
[65 FR 2315, Jan. 14, 2000]
§ 582.1763 Sodium hydroxide. ( a ) *Product.* Sodium hydroxide.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1665 Ophthalmic rotary prism. ( a ) *Identification.* An ophthalmic rotary prism is a device with various prismatic powers intended to be handheld and used to measure ocular deviation in patients with latent or manifest strabismus (eye muscle deviation).
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[52 FR 33355, Sept. 2, 1987, as amended at 53 FR 35605, Sept. 14, 1988; 66 FR 38812, July 25, 2001]
I 

118TH CONGRESS 

2D SESSION H. R. 7879 

To amend the Higher Education Act of 1965 to include court-ordered receivership in the list of actions resulting in a change of ownership of 

institutions of higher education. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 5, 2024 

Ms. PORTER introduced the following bill; which was referred to the 

Committee on Education and the Workforce 

A BILL 

To amend the Higher Education Act of 1965 to include 

court-ordered receivership in the list of actions resulting 

in a change of ownership of institutions of higher education. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Student Protection 

5 Act’’. 

6 SEC. 2. ACTIONS RESULTING IN A CHANGE OF OWNERSHIP. 

7 Section 498(i)(2) of the Higher Education Act of 

8 1965 (20 U.S.C. 1099c(i)(2)) is amended— 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7879 IH

1 (1) in subparagraph (E), by striking ‘‘or’’ at 

2 the end; 

3 (2) in subparagraph (F), by striking the period 

4 at the end and inserting ‘‘; or’’; and 

5 (3) by adding at the end the following: 

6 ‘‘(G) a court-ordered receivership.’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
(logo) Rialto  

         CAPITAL

 

 

2015 Annual Statement of Servicer Compliance (Item 1123)

 

 

Pooling and Servicing Agreement (the "Pooling and Servicing Agreement") dated as of August 1, 2015 by and among Wells Fargo Commercial Mortgage Securities, Inc., as Depositor, Wells Fargo Bank, National Association as Master Servicer, Rialto Capital Advisors, LLC as Special Servicer, TriMont Real Estate Advisors, Inc. as Trust Advisor, Wells Fargo Bank, National Association as Certificate Administrator, as Tax Administrator and as Custodian, and Wilmington Trust, National Association as Trustee relating to the Wells Fargo Commercial Mortgage Trust 2015-SG 1, Commercial Mortgage Pass-Through Certificates, Series 2015-SG1 **(WFCM 2015-SGl)**

 

The undersigned, a duly authorized officer of Rialto Capital Advisors, LLC, as special servicer (the "Special Servicer") herein certifies to the following:

 

1. All servicing activities and performance of such servicing activities under the Pooling and Servicing Agreement are performed on behalf of the Special Servicer.

 

2. A review of the servicing activities and performance by the Special Servicer for the period of August 27, 2015 to December 31, 2015 (the "Reporting Period") in accordance with the Pooling and Servicing Agreement has been conducted under my supervision.

 

3. To the best of my knowledge, based on such review, the Special Servicer has fulfilled all of its obligations under the terms of the Pooling and Servicing Agreement, in all material respects for the Reporting Period and if there has been a failure to fulfill any such obligations in any material respect, each failure and the nature and status thereof has been specifically identified herein.

 

 

Certified by: /s/ Adam Singer

Adam Singer, Managing Director 

 

Date: March l, 2016
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.4360 Electric cranial drill motor. ( a ) *Identification.* An electric cranial drill motor is an electrically operated power source used with removable rotating surgical cutting tools or drill bits on a patient's skull.
( b ) *Classification.* Class II (performance standards).
#### BROADWELL *v.*FIELD.

Accounting — Fiduciary Relations — Appeal and Error — Trusts — Attorney and Client.

Evidence in a suit for an accounting considered and *held,*to sustain the decree of the circuit court applying the rules applicable to the relation of attorney and client and of trustee and beneficiary.

Appeal from Wayne; Collingwood, J., presiding.

Submitted April 16, 1915.

(Docket No. 138.)

Decided June 7, 1915.

Bill by Allie M. Broadwell against John F. Field and others for an accounting. From a decree for complainant, defendants appeal.

Affirmed.

*Harry H. Wait (Lyle G. Younglove,*of counsel), for complainant.

*W. I. Robinson*and *R. Á. Hawley,*for defendants.

Ostrander, J.

One purpose of the bill of complaint filed in this cause was to secure an accounting and settlement with defendant Donovan as trustee, and also as attorney and legal adviser of complainant. The appeal involves only the decree of the court below made upon the accounting. No questions of law are involved, except that there must be applied, and there was applied in the court below, the rules of law applicable as between a trustee and the *cestui que trust*and an attorney and client. An examination of the record has satisfied us that the court below reached a proper conclusion, and its decree ought not to be disturbed. It is affirmed, with costs of this appeal to complainant.

Brooke, C. J., and McAlvay, Kuhn, Stone, Bird, Moore, and Steere, JJ., concurred.
Nemo

Piedmont

Meade

Pennington

Lawrence

Pennington

Meade

Lawrence

T03NR05E

T03NR06E

T02NR06E T02NR05E

T03NR07E

T04NR05E

T02NR07E

T03NR04E

T04NR06E

T02NR04E

T04NR04E

1

7

6

2

8

4

8

8

3

1

2

9

4

5 4

5

3

5

7

7

2 1

3

9

8

9

6

5

4

9

7

6

8

6

6

7

7

5

8

1

1

11

12

11

11

11

18

31

19

30

31

36

34 32

24

33

25

12

16

26

12

10

36

13

34

14

23

33

32

21

35

17

28

27

12

14

23 24

13

10

22

27 25

31

16

22

15

19

20

29

32 33

10

26

10

21

30

15

35

35

29

31

18

30 28

19

18

34

20

17

36

17

20

29

31 32

32

33

12

36

25

24

13

12

36

13 18 15 14 17

13 18 17 16 14

15 13 18 17 16

25 30 29 28 27

9

0 0.5 1 2 3

Miles

Steamboat Project Area

Alternative D Structural Stage

Steamboat Boundary

Private Land

Structural Stage

1

2

3A

3B

3C

4A

4B

4C

5

/
### Michigan Supreme Court Lansing, Michigan

Marilyn Kelly,
Chief Justice

Michael F. Cavanag h
Elizabeth A. Weave r

Maura D. Corriga n Robert P. Young, Jr. Stephen J. Markma n Diane M. Hathaway,
J ustices

I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

_______________________________________ __ Clerk September 28, 2009

0921 

# Order

September 28, 2009

139001

CHARLES C. ADAMS, Plaintiff-Appellee,

v SC: 139001 COA: 289518 WCAC: 07-000278 EATON CORPORATION and OLD REPUBLIC INSURANCE COMPANY, Defendants-Appellants.

________________ _______________ __________/

On order of the Court, the application for leave to appe al the April 23, 2009 order of the Court of Appeals is considered, and it is DENIED, because we are not persuaded that the questions presented should be reviewed by this Court.
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3950 In vitro human immunodeficiency virus (HIV) drug resistance genotype assay. ( a ) *Identification.* The in vitro HIV drug resistance genotype assay is a device that consists of nucleic acid reagent primers and probes together with software for predicting drug resistance/susceptibility based on results obtained with these primers and probes. It is intended for use in detecting HIV genomic mutations that confer resistance to specific antiretroviral drugs, as an aid in monitoring and treating HIV infection.
( b ) *Classification.* Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: In Vitro HIV Drug Resistance Genotype Assay.” See § 866.1(e) for the availability of this guidance document.
[72 FR 44382, Aug. 8, 2007]
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM CONSOLIDATED
FINANCIAL STATEMENTS OF MOSAIX, INC. AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH 10K.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                           5,423
<SECURITIES>                                    23,131
<RECEIVABLES>                                   32,913
<ALLOWANCES>                                     2,076
<INVENTORY>                                        591
<CURRENT-ASSETS>                                65,647
<PP&E>                                          29,380
<DEPRECIATION>                                  21,708
<TOTAL-ASSETS>                                  74,058
<CURRENT-LIABILITIES>                           26,190
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           108
<OTHER-SE>                                      47,760
<TOTAL-LIABILITY-AND-EQUITY>                    74,058
<SALES>                                         66,791
<TOTAL-REVENUES>                               110,068
<CGS>                                           20,415
<TOTAL-COSTS>                                   46,073
<OTHER-EXPENSES>                                60,718
<LOSS-PROVISION>                                   264
<INTEREST-EXPENSE>                                  30
<INCOME-PRETAX>                                  5,164
<INCOME-TAX>                                       924
<INCOME-CONTINUING>                              4,240
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     4,240
<EPS-PRIMARY>                                     0.36
<EPS-DILUTED>                                     0.35
        

</TABLE>
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7983 Reported in House (RH)]

<DOC>

                                                 Union Calendar No. 726
118th CONGRESS
  2d Session
                                H. R. 7983

                          [Report No. 118-889]

  To amend the Internal Revenue Code of 1986 to define the term free 
       trade agreement for purposes of the clean vehicle credit.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 15, 2024

Mrs. Fischbach introduced the following bill; which was referred to the 
                      Committee on Ways and Means

                           December 17, 2024

  Reported with an amendment, committed to the Committee of the Whole 
       House on the State of the Union, and ordered to be printed
 [Strike out all after the enacting clause and insert the part printed 
                               in italic]
 [For text of introduced bill, see copy of bill as introduced on April 
                               15, 2024]

_______________________________________________________________________

                                 A BILL

 
  To amend the Internal Revenue Code of 1986 to define the term free 
       trade agreement for purposes of the clean vehicle credit.

 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Stop Executive Overreach on Trade 
Agreements Act''.

SEC. 2. FREE TRADE AGREEMENT DEFINED FOR PURPOSES OF CLEAN VEHICLE 
              CREDIT.

    (a) In General.--Section 30D(e)(1) of the Internal Revenue Code of 
1986 is amended by adding at the end the following new subparagraph:
                    ``(C) Free trade agreement.--For purposes of 
                subparagraph (A)(i)(II), the term `free trade 
                agreement' means an international agreement approved by 
                Congress that eliminates duties and other restrictive 
                regulations of commerce on substantially all the trade 
                between the United States and 1 or more other 
                countries.''.
    (b) Effective Date.--The amendment made by this section shall apply 
to vehicles placed in service after the date of the enactment of this 
Act.
                                                 Union Calendar No. 726

118th CONGRESS

  2d Session

                               H. R. 7983

                          [Report No. 118-889]

_______________________________________________________________________

                                 A BILL

  To amend the Internal Revenue Code of 1986 to define the term free 
       trade agreement for purposes of the clean vehicle credit.

_______________________________________________________________________

                           December 17, 2024

  Reported with an amendment, committed to the Committee of the Whole 
       House on the State of the Union, and ordered to be printed
```
§ 876.1080 Gastroenterology-urology accessories to a biopsy instrument. ( a ) *Identification.* A gastroenterology-urology accessory to a biopsy instrument is an accessory used to remove a specimen of tissue for microscopic examination by cutting or aspiration. This generic type of device includes a syringe for specimen aspiration and a biopsy channel adaptor. This device does not include accessories to biopsy instruments used in other medical specialty areas.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
[84 FR 14869, Apr. 12, 2019]